HIV Clinical Trial Landscape
Data updated: May 20, 2026
2,254 clinical trials tracked since 2008
Human Immunodeficiency Virus (HIV) is a virus that attacks the body's immune system. If left untreated, HIV can lead to Acquired Immunodeficiency Syndrome (AIDS). As of 2024, there are 2,249 HIV clinical trials registered since 2008, with 305 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 1 and Phase 2, with 88 and 121 trials respectively, while Phase 3 accounts for 72 active trials and Phase 4 accounts for 60. Industry sponsorship is led by ViiV Healthcare, which currently sponsors 24 active trials, followed by Gilead with 22 active trials. Merck sponsors 11 active trials, while Johnson & Johnson and TaiMed Biologics Inc. sponsor 2 and 1 active trials, respectively. The high volume of Phase 1 and 2 trials suggests a focus on early-stage development and exploration of novel therapeutic approaches in the HIV clinical pipeline.
303 active
/
2254 total (since 2008)
91
Phase 1 Active
844 total
122
Phase 2 Active
732 total
67
Phase 3 Active
440 total
62
Phase 4 Active
466 total
Top Industry Sponsors
Sorted by active Active Done Failed
ViiV Healthcare 23 155 17
Gilead 21 69 5
Merck 11 42 9
Jecho Biopharmaceuticals Co., Ltd. 2 0 0
Johnson & Johnson 1 8 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07266831 RECRUITING
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Merck Sharp & Dohme LLC n=570
NCT07044297 RECRUITING
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Merck Sharp & Dohme LLC n=4,390
NCT02842086 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Gilead Sciences n=5,399
NCT07071623 RECRUITING
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Merck Sharp & Dohme LLC n=4,580
+ 435 more Phase 3 trials — see full database below
HIV — Trials Started by Year (last 10 years)
2016 116
2017 117
2018 110
2019 111
2020 83
2021 84
2022 86
2023 92
2024 80
2025 78
2026 49
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
ViiV Healthcare 195
Gilead 95
Merck 62
Jecho Biopharmaceuticals Co., Ltd. 2
Johnson & Johnson 10
TaiMed Biologics Inc. 9
United BioPharma 7
Shanxi Kangbao Biological Product Co., Ltd. 6
Immuno Cure Holding (HK) Limited 2
Henan Genuine Biotech Co., Ltd. 2
Active Trials by Phase
Phase 1 91
Phase 2 122
Phase 3 67
Phase 4 62
Enrollment Size Distribution
1-50 1,077
51-200 644
201-500 242
501-1k 129
1k+ 81
All Industry Sponsors
Sorted by active Active Done Failed
ViiV Healthcare 23 155 17
Gilead 21 69 5
Merck 11 42 9
Jecho Biopharmaceuticals Co., Ltd. 2 0 0
Johnson & Johnson 1 8 1
TaiMed Biologics Inc. 1 7 1
United BioPharma 1 4 2
Shanxi Kangbao Biological Product Co., Ltd. 1 5 0
Immuno Cure Holding (HK) Limited 1 1 0
Henan Genuine Biotech Co., Ltd. 1 1 0
Excision BioTherapeutics 1 1 0
BioNTech SE 1 0 0
Jiangsu Aidea Pharmaceutical Group Co., Ltd. 1 0 0
Code Pharma 1 0 0
MGB Pharma 1 0 0
NCT07266831 RECRUITING
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Merck Sharp & Dohme LLC n=570
NCT07044297 RECRUITING
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Merck Sharp & Dohme LLC n=4,390
NCT02842086 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Gilead Sciences n=5,399
NCT07071623 RECRUITING
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Merck Sharp & Dohme LLC n=4,580
NCT06630286 ACTIVE NOT RECRUITING
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
Gilead Sciences n=609
NCT02016924 ACTIVE NOT RECRUITING
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
Gilead Sciences n=133
NCT06694805 RECRUITING
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
ViiV Healthcare n=332
NCT06544733 ACTIVE NOT RECRUITING
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Gilead Sciences n=675
NCT04994509 ACTIVE NOT RECRUITING
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Gilead Sciences n=5,368
NCT02881320 ACTIVE NOT RECRUITING
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
Gilead Sciences n=177
NCT02938520 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
ViiV Healthcare n=631
NCT05994742 ACTIVE NOT RECRUITING
An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM
Queen Mary University of London n=674
NCT04150068 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Gilead Sciences n=72
NCT05917509 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
ViiV Healthcare n=171
NCT04337450 ACTIVE NOT RECRUITING
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
PENTA Foundation n=386
NCT07047716 RECRUITING
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
Gilead Sciences n=350
NCT02369406 ACTIVE NOT RECRUITING
Early Infant HIV Treatment in Botswana
Harvard School of Public Health (HSPH) n=67
NCT04851015 RECRUITING
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
Todd C. Lee MD MPH FIDSA n=416
NCT07393659 NOT YET RECRUITING
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
ViiV Healthcare n=183
NCT05411237 NOT YET RECRUITING
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
AIDS Malignancy Consortium n=130
NCT04255849 ACTIVE NOT RECRUITING
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
Weill Medical College of Cornell University n=700
NCT06532656 RECRUITING
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
Gilead Sciences n=75
NCT06203132 RECRUITING
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
ANRS, Emerging Infectious Diseases n=610
NCT04951986 ACTIVE NOT RECRUITING
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
University of Cape Town n=732
NCT02951052 ACTIVE NOT RECRUITING
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ViiV Healthcare n=618
NCT04776252 ACTIVE NOT RECRUITING
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
Merck Sharp & Dohme LLC n=2,000
NCT04925752 ACTIVE NOT RECRUITING
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
Gilead Sciences n=3,292
NCT06134362 RECRUITING
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
ViiV Healthcare n=3,508
NCT05766501 ACTIVE NOT RECRUITING
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
Merck Sharp & Dohme LLC n=641
NCT06790342 NOT YET RECRUITING
Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya
University of Chicago n=300
NCT06317051 ACTIVE NOT RECRUITING
Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)
Kirby Institute n=300
NCT05979311 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
ViiV Healthcare n=473
NCT05631093 ACTIVE NOT RECRUITING
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Merck Sharp & Dohme LLC n=553
NCT05630755 ACTIVE NOT RECRUITING
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Merck Sharp & Dohme LLC n=514
NCT06630299 ACTIVE NOT RECRUITING
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
Gilead Sciences n=600
NCT06333808 ACTIVE NOT RECRUITING
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
Gilead Sciences n=577
NCT05705349 ACTIVE NOT RECRUITING
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
Merck Sharp & Dohme LLC n=537
NCT05502341 ACTIVE NOT RECRUITING
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
Gilead Sciences n=689
NCT03164564 ACTIVE NOT RECRUITING
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
National Institute of Allergy and Infectious Diseases (NIAID) n=3,224
NCT05556720 ACTIVE NOT RECRUITING
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Monash University n=960
NCT06497465 RECRUITING
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Johns Hopkins University n=150
NCT06747507 RECRUITING
Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
University of Nairobi n=392
NCT05580666 RECRUITING
Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
Population Health Research Institute n=8,000
NCT03635788 ACTIVE NOT RECRUITING
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
National Institute of Allergy and Infectious Diseases (NIAID) n=456
NCT07075146 RECRUITING
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
José Antonio Mata Marín n=306
NCT03299049 ACTIVE NOT RECRUITING
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
ViiV Healthcare n=1,049
NCT02362503 ACTIVE NOT RECRUITING
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
ViiV Healthcare n=371
NCT05413122 RECRUITING
Evaluating Smoking Cessation Interventions for PWH in South Africa
Johns Hopkins University n=660
NCT05813964 RECRUITING
Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.
ANRS, Emerging Infectious Diseases n=524
NCT05786547 RECRUITING
V+PSF-M for Tobacco Cessation in HIV Care in India
University of Colorado, Denver n=400
NCT00796263 RECRUITING
Antiretroviral Therapy for Acute and Chronic HIV Infection
SEARCH Research Foundation n=900
NCT05924438 ACTIVE NOT RECRUITING
A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy
Professor Francois Venter n=600
NCT03785106 ACTIVE NOT RECRUITING
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
The HIV Netherlands Australia Thailand Research Collaboration n=2,500
NCT06550804 RECRUITING
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
University of Illinois at Chicago n=126
NCT05515770 RECRUITING
The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir
Evandro Chagas National Institute of Infectious Disease n=1,200
NCT05546242 ACTIVE NOT RECRUITING
Improving HIV-1 Control in Africa with Long Acting Antiretrovirals
MRC/UVRI and LSHTM Uganda Research Unit n=540
NCT06587542 NOT YET RECRUITING
Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient
Universitas Padjadjaran n=30
NCT06507059 RECRUITING
Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
Chang Gung Memorial Hospital n=40
NCT06138600 ACTIVE NOT RECRUITING
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
University of Witwatersrand, South Africa n=200
NCT06133686 NOT YET RECRUITING
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa
MRC/UVRI and LSHTM Uganda Research Unit n=400
NCT04892654 RECRUITING
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
Chelsea and Westminster NHS Foundation Trust n=150
NCT04406727 NOT YET RECRUITING
UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
United BioPharma n=50
NCT05085171 RECRUITING
An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease
Makerere University n=2,400
NCT00980538 COMPLETED
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
Janssen Sciences Ireland UC n=180
NCT04652700 TERMINATED
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
Merck Sharp & Dohme LLC n=494
NCT02968849 COMPLETED
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
National Institute of Allergy and Infectious Diseases (NIAID) n=5,404
NCT05378399 COMPLETED
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
Brigham and Women's Hospital n=40
NCT05168813 COMPLETED
Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
COVID-19 Prevention Network n=14,237
NCT06613685 TERMINATED
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
Gilead Sciences n=73
NCT01453192 COMPLETED
Renal Transplantation and Raltegravir in HIV-Infected Patients
ANRS, Emerging Infectious Diseases n=27
NCT03256422 COMPLETED
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
ANRS, Emerging Infectious Diseases n=640
NCT00670839 COMPLETED
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)
ANRS, Emerging Infectious Diseases n=178
NCT02987530 COMPLETED
National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection
ANRS, Emerging Infectious Diseases n=101
NCT04223791 COMPLETED
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
Merck Sharp & Dohme LLC n=643
NCT02720094 COMPLETED
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
National Institute of Allergy and Infectious Diseases (NIAID) n=4,570
NCT02859961 COMPLETED
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
CytoDyn, Inc. n=562
NCT04223778 COMPLETED
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
Merck Sharp & Dohme LLC n=672
NCT03016533 COMPLETED
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
ViiV Healthcare n=100
NCT04644029 TERMINATED
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Merck Sharp & Dohme LLC n=730
NCT04233879 COMPLETED
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Merck Sharp & Dohme LLC n=599
NCT03284866 COMPLETED
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
AIDS Malignancy Consortium n=536
NCT01854775 COMPLETED
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Gilead Sciences n=129
NCT03207945 COMPLETED
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
University of California, San Francisco n=118
NCT02302547 COMPLETED
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
University Hospital, Tours n=224
NCT04738812 COMPLETED
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
ANRS, Emerging Infectious Diseases n=1,330
NCT04742491 COMPLETED
Pre-Exposure Prophylaxis for Transgender Women in the US and South America
HIV Prevention Trials Network n=304
NCT03682848 COMPLETED
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
ViiV Healthcare n=32
NCT05911360 COMPLETED
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ViiV Healthcare n=203
NCT02990858 TERMINATED
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
CytoDyn, Inc. n=43
NCT05271370 TERMINATED
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
CytoDyn, Inc. n=56
NCT03913195 COMPLETED
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
TaiMed Biologics Inc. n=43
NCT03915366 COMPLETED
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Hospital Universitario 12 de Octubre n=563
NCT03512418 COMPLETED
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)
Brigham and Women's Hospital n=30
NCT02245022 COMPLETED
Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study
University of Liverpool n=60
NCT02344290 COMPLETED
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID) n=7,769
NCT01718301 TERMINATED
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
Anna Cruceta n=108
NCT03965923 COMPLETED
Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy
National Institute of Allergy and Infectious Diseases (NIAID) n=1,104
NCT02059499 COMPLETED
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
AIDS Malignancy Consortium n=91
NCT04193189 COMPLETED
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
National Institute of Allergy and Infectious Diseases (NIAID) n=638
NCT03311945 COMPLETED
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Judit Pich n=33
NCT02285114 COMPLETED
Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen
Gilead Sciences n=41
NCT03029689 COMPLETED
Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia n=61
NCT05601128 COMPLETED
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) n=12
NCT03333083 TERMINATED
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
Judit Pich n=17
NCT03231358 COMPLETED
Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
Brown University n=1,758
NCT01233531 COMPLETED
Effects of Cash Transfer for the Prevention of HIV in Young South African Women
HIV Prevention Trials Network n=2,537
NCT03547908 COMPLETED
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
Gilead Sciences n=244
NCT04034862 COMPLETED
Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs
University of Liege n=36
NCT02460900 COMPLETED
Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke
University of Maryland, Baltimore n=184
NCT03249181 COMPLETED
Dolutegravir in Pregnant HIV Mothers and Their Neonates
University of Liverpool n=268
NCT03342027 COMPLETED
Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya
University of Maryland, Baltimore n=300
NCT03227861 COMPLETED
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
Janssen Scientific Affairs, LLC n=109
NCT04233216 COMPLETED
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
Merck Sharp & Dohme LLC n=35
NCT05349838 COMPLETED
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NEAT ID Foundation n=140
NCT05896748 COMPLETED
Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study
ViiV Healthcare n=94
NCT02403674 COMPLETED
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
Merck Sharp & Dohme LLC n=734
NCT02397096 COMPLETED
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
Merck Sharp & Dohme LLC n=673
NCT03070223 COMPLETED
PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=602
NCT03563742 TERMINATED
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Janssen Research & Development, LLC n=58
NCT01854762 TERMINATED
Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
Fundação Bahiana de Infectologia n=33
NCT03671109 COMPLETED
Improving Maternal heAlth by Reducing Malaria in African HIV Women
Barcelona Institute for Global Health n=666
NCT02275780 COMPLETED
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Merck Sharp & Dohme LLC n=769
NCT05592613 COMPLETED
Next Generation Ingestible Sensors for Medication Adherence Measurement
Brigham and Women's Hospital n=15
NCT04937881 COMPLETED
PK of TAF and TDF for PrEP in Pregnant and Postpartum Women
University of California, Los Angeles n=39
NCT02422797 COMPLETED
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
ViiV Healthcare n=518
NCT02429791 COMPLETED
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
ViiV Healthcare n=510
NCT02135419 COMPLETED
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
AIDS Malignancy Consortium n=4,446
NCT04121195 COMPLETED
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
University of Liverpool n=26
NCT04542070 COMPLETED
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
ViiV Healthcare n=687
NCT06403787 COMPLETED
Effect of Aerobic Training and Ginkgo Biloba on Lipids Levels in HIV-positive Patients Undergoing Antiretroviral Treatment
University of Guadalajara n=28
NCT01480713 COMPLETED
Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
IrsiCaixa n=41
NCT04399551 COMPLETED
A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries
ViiV Healthcare n=437
NCT03092817 COMPLETED
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
Oxford University Clinical Research Unit, Vietnam n=520
NCT03727152 COMPLETED
Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir
The HIV Netherlands Australia Thailand Research Collaboration n=170
NCT01910402 COMPLETED
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
ViiV Healthcare n=499
NCT01511809 COMPLETED
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
IRCCS San Raffaele n=117
NCT03493568 TERMINATED
Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)
IRCCS San Raffaele n=100
NCT04653194 COMPLETED
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
Chelsea and Westminster NHS Foundation Trust n=36
NCT01620944 TERMINATED
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
Bristol-Myers Squibb n=3
NCT01605084 WITHDRAWN
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
Bristol-Myers Squibb
NCT01837277 COMPLETED
Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients
Fundação Bahiana de Infectologia n=186
NCT02831764 COMPLETED
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
ViiV Healthcare n=722
NCT02486133 COMPLETED
Dual Therapy With Boosted Darunavir + Dolutegravir
Technical University of Munich n=269
NCT04021290 COMPLETED
Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)
ViiV Healthcare n=493
NCT04808973 COMPLETED
DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women
Fundação Bahiana de Infectologia n=20
NCT05896761 COMPLETED
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
ViiV Healthcare n=118
NCT03178084 COMPLETED
Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal n=721
NCT02831673 COMPLETED
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
ViiV Healthcare n=719
NCT04140266 COMPLETED
Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs
National Institute of Allergy and Infectious Diseases (NIAID) n=394
NCT04433780 COMPLETED
DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV
Professor Francois Venter n=133
NCT03446573 COMPLETED
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)
ViiV Healthcare n=743
NCT03149211 WITHDRAWN
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults
United BioPharma
NCT04001803 COMPLETED
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)
ViiV Healthcare n=115
NCT02227238 COMPLETED
Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
ViiV Healthcare n=627
NCT03656783 COMPLETED
Effects of Biktarvy on CFR in Stable HIV Patients
Brigham and Women's Hospital n=25
NCT03122262 COMPLETED
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
Professor Francois Venter n=1,110
NCT01617096 COMPLETED
Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
International Partnership for Microbicides, Inc. n=2,629
NCT03870438 COMPLETED
Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention
ANRS, Emerging Infectious Diseases n=1,506
NCT03048422 COMPLETED
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
National Institute of Allergy and Infectious Diseases (NIAID) n=643
NCT02660905 COMPLETED
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Ottawa Hospital Research Institute n=25
NCT03227731 COMPLETED
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women
University of KwaZulu n=540
NCT02483078 COMPLETED
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
CytoDyn, Inc. n=52
NCT01607541 COMPLETED
Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV
New York University n=3,400
NCT01281813 COMPLETED
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
Janssen Sciences Ireland UC n=145
NCT02858037 COMPLETED
Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
International Partnership for Microbicides, Inc. n=1,456
NCT02862171 COMPLETED
To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women
International Partnership for Microbicides, Inc. n=941
NCT02075593 COMPLETED
ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection
ViiV Healthcare n=4
NCT02434848 COMPLETED
A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses
Sheffield Teaching Hospitals NHS Foundation Trust n=13
NCT01197027 COMPLETED
Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection
HIV Prevention Trials Network n=28
NCT04079452 COMPLETED
Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia n=15
NCT03275350 COMPLETED
Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
Oregon Health and Science University n=114
NCT05306704 COMPLETED
High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial
University of the Punjab n=95
NCT03403569 COMPLETED
Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection
Peking Union Medical College Hospital n=353
NCT02817451 COMPLETED
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
Sanofi Pasteur, a Sanofi Company n=53
NCT01231516 COMPLETED
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
ViiV Healthcare n=724
NCT02607956 COMPLETED
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=657
NCT02607930 COMPLETED
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=631
NCT01061151 COMPLETED
Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
National Institute of Allergy and Infectious Diseases (NIAID) n=3,747
NCT03110380 COMPLETED
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
Gilead Sciences n=567
NCT02269917 COMPLETED
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
Janssen R&D Ireland n=1,149
NCT00270257 TERMINATED
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
National Institute of Allergy and Infectious Diseases (NIAID) n=1,251
NCT01172535 COMPLETED
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
National Institute of Allergy and Infectious Diseases (NIAID) n=97
NCT01404312 COMPLETED
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
National Institute of Allergy and Infectious Diseases (NIAID) n=3,000
NCT00537394 COMPLETED
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
National Institute of Allergy and Infectious Diseases (NIAID) n=517
NCT03129113 COMPLETED
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
University College, London n=90
NCT01482767 COMPLETED
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
National Institute of Allergy and Infectious Diseases (NIAID) n=262
NCT01461096 COMPLETED
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
National Institute of Allergy and Infectious Diseases (NIAID) n=575
NCT01511237 COMPLETED
Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers
Institut de Recherche pour le Developpement n=379
NCT03945981 COMPLETED
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
ViiV Healthcare n=131
NCT01435018 COMPLETED
Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=334
NCT01896921 COMPLETED
Switch to Maraviroc + Integrase Inhibitor
University of Maryland, Baltimore n=7
NCT03631732 COMPLETED
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Gilead Sciences n=496
NCT02777229 COMPLETED
Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings
ANRS, Emerging Infectious Diseases n=616
NCT01510340 COMPLETED
Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management
Centre hospitalier de l'Université de Montréal (CHUM) n=217
NCT01352715 COMPLETED
Study of Options for Second-Line Effective Combination Therapy (SELECT)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=515
NCT03297216 COMPLETED
Improving Pregnancy Outcomes With Progesterone
University of North Carolina, Chapel Hill n=800
NCT02738138 COMPLETED
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
AbbVie n=153
NCT01939197 COMPLETED
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
AbbVie n=318
NCT02499978 WITHDRAWN
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Stanford University
NCT01815736 COMPLETED
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
Gilead Sciences n=1,443
NCT02383108 COMPLETED
Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children
PENTA Foundation n=318
NCT02104700 COMPLETED
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Philip Grant n=150
NCT02707861 COMPLETED
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
TaiMed Biologics Inc. n=79
NCT01266902 COMPLETED
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Janssen R&D Ireland n=482
NCT01709084 COMPLETED
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
Janssen-Cilag International NV n=426
NCT01145417 TERMINATED
Pregabalin Trial In HIV Neuropathic Pain
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=217
NCT02178592 COMPLETED
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
ViiV Healthcare n=113
NCT02603107 COMPLETED
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
Gilead Sciences n=578
NCT02797587 COMPLETED
Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)
Boston Medical Center n=400
NCT03525210 COMPLETED
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Universitaire Ziekenhuizen KU Leuven n=271
NCT03405935 COMPLETED
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
Gilead Sciences n=86
NCT01746199 COMPLETED
Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum
Institut Pasteur n=193
NCT02603120 COMPLETED
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
Gilead Sciences n=567
NCT03708861 WITHDRAWN
Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
University of Turin, Italy
NCT01882361 COMPLETED
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
University of Pennsylvania n=77
NCT02600819 COMPLETED
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
Gilead Sciences n=55
NCT02478632 COMPLETED
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen
ViiV Healthcare n=102
NCT03327155 COMPLETED
Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial
Kirby Institute n=900
NCT01731691 TERMINATED
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
Institute for Human Genetics and Biochemistry n=12
NCT01374490 COMPLETED
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Bausch Health Americas, Inc. n=250
NCT04360759 WITHDRAWN
Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19
University of Cape Town
NCT03517358 COMPLETED
Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol
University of California, Davis n=10
NCT02616029 COMPLETED
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
Gilead Sciences n=66
NCT02305927 COMPLETED
Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health
Wafaie Fawzi n=2,300
NCT01792570 COMPLETED
DRV/r + RPV QD: Efficacy and Toxicity Reduction
ASST Fatebenefratelli Sacco n=37
NCT02475629 COMPLETED
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
TaiMed Biologics Inc. n=40
NCT02121795 COMPLETED
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Gilead Sciences n=668
NCT02652624 COMPLETED
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
Gilead Sciences n=472
NCT02616783 COMPLETED
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
Gilead Sciences n=167
NCT01797445 COMPLETED
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=872
NCT01818596 COMPLETED
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Gilead Sciences n=252
NCT01011413 COMPLETED
Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.
Kirby Institute n=636
NCT02358226 COMPLETED
HIV & Drug Abuse Prevention for South African Men
University of California, Los Angeles n=1,211
NCT03595709 COMPLETED
Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan
Yu-Jay Corp. n=50
NCT00808002 COMPLETED
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
Germans Trias i Pujol Hospital n=30
NCT01034917 COMPLETED
Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
Germans Trias i Pujol Hospital n=43
NCT02345252 COMPLETED
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Gilead Sciences n=632
NCT02345226 COMPLETED
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
Gilead Sciences n=881
NCT01691768 COMPLETED
Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Centre for the AIDS Programme of Research in South Africa n=372
NCT01352117 COMPLETED
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=192
NCT02976259 COMPLETED
Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba n=20
NCT02980016 COMPLETED
Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
The Aurum Institute NPC n=4,027
NCT02469246 COMPLETED
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
Gilead Sciences n=567
NCT02263326 COMPLETED
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
Babafemi Taiwo n=89
NCT02426112 COMPLETED
Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children
London School of Hygiene and Tropical Medicine n=347
NCT01705574 COMPLETED
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
Gilead Sciences n=583
NCT02155101 COMPLETED
Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS
University of Liverpool n=120
NCT04067869 COMPLETED
Cytomegalovirus Infection in Patients With HIV-1 Infection
University Hospital, Bordeaux n=392
NCT01798680 COMPLETED
Trial of Vitamin D in HIV Progression
Harvard School of Public Health (HSPH) n=4,000
NCT02426840 COMPLETED
Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents
Chiang Mai University n=200
NCT02068846 COMPLETED
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
University of North Carolina, Chapel Hill n=17
NCT02600325 COMPLETED
Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
Erasmus Medical Center n=80
NCT02346487 COMPLETED
Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)
Drugs for Neglected Diseases n=1,003
NCT00993031 COMPLETED
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
University of California, San Francisco n=389
NCT01900106 COMPLETED
A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)
University of Modena and Reggio Emilia n=47
NCT00557245 COMPLETED
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
University of Washington n=4,758
NCT00933790 COMPLETED
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Tuberculosis Research Centre, India n=331
NCT01227044 COMPLETED
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Yale University n=51
NCT02282293 COMPLETED
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)
University of California, San Francisco n=200
NCT03369327 COMPLETED
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
Tehran University of Medical Sciences n=232
NCT02692027 COMPLETED
Same-day ART Initiation Versus Standard of Care After Positive HIV-test Result in Rural Lesotho
Swiss Tropical & Public Health Institute n=276
NCT01360762 COMPLETED
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Institute of Tropical Medicine, Belgium n=74
NCT02998320 COMPLETED
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux n=101
NCT02003703 COMPLETED
Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .
Universidad de Valparaiso n=107
NCT02131233 COMPLETED
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
Merck Sharp & Dohme LLC n=802
NCT01426243 COMPLETED
The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.
French National Agency for Research on AIDS and Viral Hepatitis n=71
NCT02273765 COMPLETED
Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
ANRS, Emerging Infectious Diseases n=460
NCT00978068 COMPLETED
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
University of California, San Francisco n=176
NCT01780506 COMPLETED
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=872
NCT02276612 COMPLETED
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
Gilead Sciences n=60
NCT02073656 COMPLETED
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Gilead Sciences n=335
NCT01967940 COMPLETED
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Gilead Sciences n=55
NCT02071082 COMPLETED
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Gilead Sciences n=79
NCT01968551 COMPLETED
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Gilead Sciences n=158
NCT02605954 COMPLETED
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
Gilead Sciences n=275
NCT02707601 COMPLETED
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Gilead Sciences n=150
NCT02596334 TERMINATED
Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients
Centre Hospitalier Régional d'Orléans n=158
NCT01335698 COMPLETED
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
Bristol-Myers Squibb n=160
NCT00678587 TERMINATED
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
GlaxoSmithKline n=292
NCT01427543 COMPLETED
The HJ MILE HIV Prevention Intervention for Post-incarcerated Men
University of Southern California n=212
NCT01227824 COMPLETED
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
ViiV Healthcare n=828
NCT02489461 COMPLETED
Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy
Viriom n=150
NCT01721109 COMPLETED
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Gilead Sciences n=50
NCT02103439 COMPLETED
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
Biocad n=140
NCT01923311 TERMINATED
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
Gilead Sciences n=31
NCT00625404 COMPLETED
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
FHI 360 n=2,120
NCT01625091 COMPLETED
Clinical Trial to Reduce Drinking in Women With HIV
University of Florida n=194
NCT00855335 COMPLETED
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Janssen Scientific Affairs, LLC n=77
NCT01568892 COMPLETED
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
ViiV Healthcare n=30
NCT02671383 COMPLETED
Evaluation of Low-dose Darunavir in a Switch Study
Willem Daniel Francois Venter n=300
NCT01106638 COMPLETED
A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)
Montefiore Medical Center n=147
NCT01263015 COMPLETED
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
ViiV Healthcare n=844
NCT01523496 COMPLETED
Vitamin D Supplementation in HIV Youth
University Hospitals Cleveland Medical Center n=190
NCT00860977 COMPLETED
Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
University Health Network, Toronto n=202
NCT01924286 COMPLETED
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
University of Cape Town n=240
NCT01449929 COMPLETED
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
ViiV Healthcare n=488
NCT01448707 COMPLETED
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Janssen-Cilag International NV n=274
NCT01070017 COMPLETED
Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru
Brigham and Women's Hospital n=1,244
NCT01701882 COMPLETED
A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
St Stephens Aids Trust n=40
NCT01905059 COMPLETED
Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa
ANRS, Emerging Infectious Diseases n=265
NCT01516970 COMPLETED
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Janssen-Cilag G.m.b.H n=312
NCT00729391 COMPLETED
Women-Focused HIV Prevention in the Western Cape
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) n=720
NCT03019783 COMPLETED
Atazanavir and Endothelial Function in Older HIV Patients
Brigham and Women's Hospital n=60
NCT00935480 COMPLETED
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer n=17
NCT01473472 COMPLETED
On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men
ANRS, Emerging Infectious Diseases n=400
NCT02369627 COMPLETED
Facilitating HIV Testing Among Young Adult MSM Through Social Networking
Rhode Island Hospital n=425
NCT01694420 COMPLETED
Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Duke University n=33
NCT02006745 COMPLETED
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
St Stephens Aids Trust n=20
NCT00745823 TERMINATED
A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)
Merck Sharp & Dohme LLC n=775
NCT00764946 COMPLETED
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
Merck Sharp & Dohme LLC n=209
NCT01146873 COMPLETED
Treatment Options for Protease Inhibitor-exposed Children
Columbia University n=300
NCT01349062 COMPLETED
Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS
Traditional Alternative Medicine Research, India n=1,000
NCT00928187 COMPLETED
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
ANRS, Emerging Infectious Diseases n=454
NCT01114425 COMPLETED
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux n=149
NCT02105987 COMPLETED
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
ViiV Healthcare n=555
NCT01440569 COMPLETED
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Gilead Sciences n=314
NCT02810275 COMPLETED
Folinic Acid: Supplementation and Therapy
Hospital de Clinicas de Porto Alegre n=69
NCT01131273 COMPLETED
HIV Risk Reduction in Subutex Injectors in Tbilisi
University of Pennsylvania n=68
NCT02084316 COMPLETED
Testing and Linkage to HIV Care in China
University of California, Los Angeles n=360
NCT01127204 COMPLETED
Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age
ANRS, Emerging Infectious Diseases n=161
NCT01348308 COMPLETED
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
ANRS, Emerging Infectious Diseases n=407
NCT01475838 COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Gilead Sciences n=438
NCT00708162 COMPLETED
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Gilead Sciences n=724
NCT01108510 COMPLETED
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=698
NCT01176409 COMPLETED
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
University Health Network, Toronto n=60
NCT01363011 COMPLETED
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Gilead Sciences n=106
NCT01825031 COMPLETED
Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
Anna Griffiths, MRC n=1,805
NCT01154673 COMPLETED
Effects of Intensive cART During Acute/Early HIV Infection
University of Toronto n=32
NCT00543725 COMPLETED
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Tibotec Pharmaceuticals, Ireland n=680
NCT00540449 COMPLETED
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
Tibotec Pharmaceuticals, Ireland n=694
NCT01656122 COMPLETED
Abacavir and Lamivudine PK in Children
The HIV Netherlands Australia Thailand Research Collaboration n=30
NCT02670772 COMPLETED
Dose Optimisation of Stavudine for the Treatment of HIV Infection
Willem Daniel Francois Venter n=1,077
NCT00409591 TERMINATED
Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand
Institut de Recherche pour le Developpement n=435
NCT02157311 COMPLETED
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
ANRS, Emerging Infectious Diseases n=100
NCT01345630 TERMINATED
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
ViiV Healthcare n=813
NCT01495702 COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Gilead Sciences n=439
NCT01328041 COMPLETED
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
ViiV Healthcare n=183
NCT01252940 COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Gilead Sciences n=482
NCT01966822 COMPLETED
Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia n=75
NCT01106586 COMPLETED
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=708
NCT01095796 COMPLETED
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=707
NCT01693458 COMPLETED
Positive Change Agents Program-Tanzania (Evaluation)
Harvard School of Public Health (HSPH) n=1,046
NCT02247687 TERMINATED
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
ANRS, Emerging Infectious Diseases n=4
NCT02537236 COMPLETED
Omega-3 Supplementation in HIV Patients With Therapeutic Lifestyle Change Diet.
Instituto Mexicano del Seguro Social n=200
NCT02041520 COMPLETED
Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients
Coordinación de Investigación en Salud, Mexico n=70
NCT00562510 TERMINATED
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
Pedro Cahn n=20
NCT00495651 COMPLETED
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
French National Agency for Research on AIDS and Viral Hepatitis n=2,073
NCT00669487 COMPLETED
A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP
SEARCH Research Foundation n=150
NCT01061593 COMPLETED
Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
Lisichansk Regional Tuberculosis Dispensary n=269
NCT00984152 WITHDRAWN
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Rush University Medical Center
NCT01783678 COMPLETED
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Gilead Sciences n=275
NCT01386294 COMPLETED
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
CONRAD n=2,059
NCT00709007 WITHDRAWN
Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Johns Hopkins University
NCT00785967 WITHDRAWN
Immune Responses in Patients Treated With Raltegravir
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT01307124 COMPLETED
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
The HIV Netherlands Australia Thailand Research Collaboration n=199
NCT00729924 COMPLETED
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
Vanderbilt University n=40
NCT01309243 COMPLETED
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences n=799
NCT01499199 COMPLETED
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
ViiV Healthcare n=13
NCT01427738 COMPLETED
Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=221
NCT01533259 COMPLETED
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Gilead Sciences n=48
NCT01195467 COMPLETED
Atripla to Raltegravir Switch Study for CNS Toxicity
St Stephens Aids Trust n=40
NCT01667731 COMPLETED
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Gilead Sciences n=224
NCT00962780 COMPLETED
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Pfizer n=303
NCT00819052 COMPLETED
Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
Boehringer Ingelheim n=445
NCT00887679 COMPLETED
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
Duke University n=30
NCT00887653 COMPLETED
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The Miriam Hospital n=20
NCT00947271 COMPLETED
Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
The Miriam Hospital n=1,010
NCT00811954 COMPLETED
Comparative Study of Three NNRTI-Sparing HAART Regimens
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=1,814
NCT00918307 COMPLETED
Efficacy and Safety of Varenicline Among HIV-infected Patients
ANRS, Emerging Infectious Diseases n=248
NCT00844519 COMPLETED
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
University of California, San Francisco n=52
NCT02189902 COMPLETED
Botswana Vitamin D Supplementation Study in HIV/AIDS
Children's Hospital of Philadelphia n=60
NCT00946595 COMPLETED
Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
French National Agency for Research on AIDS and Viral Hepatitis n=420
NCT01608802 COMPLETED
Outcomes for Antiretroviral Therapy Patients Receiving Palliative Care
King's College London n=240
NCT01228578 COMPLETED
Multi-vitamins, HAART and HIV/AIDS in Uganda
Harvard School of Public Health (HSPH) n=400
NCT02123433 COMPLETED
Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults
University of Siena n=50
NCT00640263 COMPLETED
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
French National Agency for Research on AIDS and Viral Hepatitis n=1,500
NCT01810731 WITHDRAWN
Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya
Centers for Disease Control and Prevention
NCT00988039 COMPLETED
Europe-Africa Research Network for Evaluation of Second-line Therapy
Justine Boles n=1,277
NCT01033760 COMPLETED
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
ANRS, Emerging Infectious Diseases n=90
NCT00849160 COMPLETED
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida n=100
NCT01543035 COMPLETED
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Calmy Alexandra n=34
NCT02005900 COMPLETED
Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=66
NCT01442428 WITHDRAWN
Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
University of Minnesota
NCT01066962 COMPLETED
Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects
ANRS, Emerging Infectious Diseases n=800
NCT01327755 COMPLETED
Rwanda Selenium Supplementation Clinical Trial
The Canadian College of Naturopathic Medicine n=300
NCT01196195 COMPLETED
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
PENTA Foundation n=173
NCT01053325 COMPLETED
Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy
Institute of Tropical Medicine, Belgium n=848
NCT01956383 COMPLETED
Safety and Efficacy of the PrePex Device Circumcision When Performed by Nurses
Ministry of Health and Child Welfare, Zimbabwe n=603
NCT01419899 COMPLETED
Increasing Viral Testing in the Emergency Department
Rhode Island Hospital n=398
NCT00727597 COMPLETED
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
Georgetown University n=101
NCT00963235 COMPLETED
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
Pfizer n=331
NCT01032408 COMPLETED
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection
Chiltern Pesquisa Clinica Ltda n=154
NCT01271894 COMPLETED
The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Kirby Institute n=40
NCT01451333 COMPLETED
The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Kirby Institute n=32
NCT01060618 COMPLETED
Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term
Asociacion para el Estudio de las Enfermedades Infecciosas n=58
NCT00619320 COMPLETED
Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women
Virginia Commonwealth University n=380
NCT00970879 COMPLETED
Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine
Institut de Recherche pour le Developpement n=430
NCT01733927 COMPLETED
An Evaluation of a Rapid Test for HIV
Pontificia Universidad Catolica de Chile n=497
NCT01255371 WITHDRAWN
A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
ANRS, Emerging Infectious Diseases
NCT01153217 COMPLETED
Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density
Germans Trias i Pujol Hospital n=54
NCT00446758 COMPLETED
Trial of Zinc and HIV Progression in Children
Harvard School of Public Health (HSPH) n=440
NCT01237444 COMPLETED
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
Pedro Cahn n=417
NCT01337583 WITHDRAWN
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa
International Partnership for Microbicides, Inc.
NCT01337570 WITHDRAWN
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa
International Partnership for Microbicides, Inc.
NCT00573001 COMPLETED
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
French National Agency for Research on AIDS and Viral Hepatitis n=120
NCT00859144 COMPLETED
Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Icahn School of Medicine at Mount Sinai n=901
NCT00936195 WITHDRAWN
Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial
French National Agency for Research on AIDS and Viral Hepatitis
NCT00711009 COMPLETED
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
Abbott n=206
NCT00612898 TERMINATED
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Avexa n=239
NCT01006031 COMPLETED
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
Sociedad Andaluza de Enfermedades Infecciosas n=25
NCT01171495 COMPLETED
Impact of Nutrition Intervention on HIV/AIDS Infected Patients
Caribbean Health Research Council n=121
NCT00528892 COMPLETED
Switching From PI to RALtegravir in HIV Stable Patients
Hospital Clinic of Barcelona n=282
NCT00690690 COMPLETED
No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks
Centers for Disease Control and Prevention n=370
NCT00792324 COMPLETED
Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125
St Stephens Aids Trust n=24
NCT00990600 COMPLETED
QoL and Adherence to One-pill Once-a-day HAART
A.O. Ospedale Papa Giovanni XXIII n=212
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only